ABSTRACT-Since neuropeptide FF (NPFF) is a putative neurotransmitter to exert anti-opioid activity, we examined the effects of [D-Tyr 1 , (NMe)Phe
The important role of an octapeptide neuropeptide FF (Phe-Leu-Phe-Gln-Pro-Gln-Arg-Phe-NH 2; NPFF) has been demonstrated in the central nervous system (1) . NPFF exerts modulatory action on morphine-induced analgesia in rodents (2, 3) . Namely, the intracerebroventricular administration of NPFF reverses morphine-induced analgesia in rats (1) . NPFF antagonizes the modulation of Ca 2+ channels by mu-opioids in isolated rat spinal ganglion and dorsal raphe neurons (4, 5) and by nociceptin in rat dorsal raphe neurons (5) . NPFF modulates the excitatory synaptic transmission through an interaction with presynaptic delta-opioid receptors in the pontine parabrachial nucleus in vitro (6) . Although these results suggest that NPFF reverses the effect of morphine or endogenous opioids, the exact mechanism of the action of NPFF at the neuronal and cellular level remains unknown.
It is well known that morphine has a marked inhibitory effect on the motility of the gastrointestinal tract in the human as well as experimental animals (7) . The inhibitory effect of morphine is mainly due to reduction in acetylcholine (ACh) release from enteric cholinergic neurons (8, 9) . In a previous report, we demonstrated that morphine inhibited ACh release from longitudinal muscle with myenteric plexus (LMMP) preparations of the guinea pig ileum when muscarinic autoinhibition was not fully activated (10) . We also demonstrated that endogenous opioids are involved in the regulation of ACh release, because naloxone increases electrical field stimulation (EFS)-evoked ACh release in the presence of atropine (11) . Thus, a LMMP preparation of guinea pig ileum seems to be a good model to study the effects of opioids or opioid antagonists on ACh release. NPFF reverses the inhibitory effect of morphine on EFSinduced contraction of guinea pig ileum (12) , but little is known about its mechanism. In the present study, we investigated the action of [D-Tyr 1 , (NMe)Phe 3 ]neuropeptide FF (1DMe) as a substitute for NPFF on the ACh release from the guinea pig LMMP preparation, since it is protected from degradation by the aminopeptidase and interacts with NPFF receptors with high affinity (Kd = 0.1 nM) (13) .
MATERIALS AND METHODS
Male guinea pigs, weighing 300 -500 g, were lightly anesthetized with diethylether and killed by bleeding. The longitudinal muscle preparations of the ileum with the myenteric plexus were made as described previously (14) . The preparation was mounted in an organ bath containing 3 ml of Tyrode solution of the following composition: 136.9 mM NaCl, 2.7 mM KCl, 1.8 mM CaCl2, 1.05 mM MgCl2, 11.9 mM NaHCO3, 0.4 mM NaH2PO4 and 5.6 mM glucose. The bathing medium was kept at 37°C and bubbled with 95% O2 and 5% CO2.
The preparations were equilibrated for 30 min by perfusion with Tyrode solution containing physostigumine salicylate (5 mM) and choline chloride (1 mM) at a rate of 1 -2 ml · min
. Then, perfusion was stopped and the bathing medium was replaced by 3 ml of fresh Tyrode solution at intervals of 1 min. After two consecutive samples were collected for the measurement of spontaneous release of ACh, the preparations were stimulated by EFS. For the EFS-induced release of ACh, the stimulation was performed in trains of 20 s at 10 Hz. Bathing fluid was collected after a further 40-s period as shown previously. These experimental procedures for sample collection were repeated 2 times with 15-min intervals. EFS was carried out with a pair of platinum electrodes, one at the top and the other at the bottom of the preparation. The parameters for EFS were as follows: supramaximal voltage (50 V), pulse duration of 0.5 ms, 200 pulses at 10 Hz. The first stimulation (S1) was carried out in the absence of test drug(s), and the second (S2) was in the presence of test drug(s). In the present study, atropine was added to Tyrode solution throughout the experiment in order to block autoinhibition by released ACh (10) . All samples collected were kept on ice until the end of the ACh release experiment and then processed for ACh determination. At the end of the experiment, the preparations were blotted and weighed. Acetylcholine release due to EFS (S1', S2') was calculated by subtracting the output of the immediately preceding spontaneous release (R1, R2) from the total output during the periods of stimulation. All results are shown as relative ACh release defined as R2/R1´100 and S2'/S1'´100.
ACh released in the medium was assayed by HPLC. For analysis by HPLC, ACh in aliquots of the medium was precipitated with KI3 in the presence of tetraethylammonium as a coprecipitant and 50 pmol ethylhomocholine as an internal standard. The quaternary ammonium compounds precipitated were dissolved with about 1 ml of acetonitrile and the solution was passed through a Bio Rad AG 1-X8 anion exchange resin column to trap I3
-in the solution. The effluents were evaporated to dryness under reduced pressure and the dried samples stored in the refrigerator until assay. At use, the dried samples were dissolved with 100 ml of water and passed through a filter (0.45-mm pore size), and 25 ml of the filtrates was injected into the HPLC assay system for ACh determination. ACh was determined by Yanaco reversed-phase HPLC (Yanaco, Kyoto), developed first by Potter et al. (15) , using a postcolumn enzyme (acetylcholinesterase plus choline oxidase) reactor (Eicom ACEnzympak; Eicom, Kyoto) instead of the enzyme-flow system of the original method.
Statistical analyses
All data in the text are expressed as the mean ± S.E.M. The statistical significance of the difference between two mean values was assessed by the unpaired Student's t-test. P values less than 0.05 were considered significant.
neuropeptide FF) was synthesized as described by Gicquel et al. (13) . Morphine hydrochloride was purchased from Takeda Chemical Industries (Osaka); naloxone hydrochloride, atropine sulfate, choline chloride and physostigmine salicylate, from Wako Pure Chemical (Osaka); Arterenol (norepinephrine bitartarate), from Sigma Chemical Co. (St. Louis, MO, USA). All other chemicals were of analytical grade. RESULTS 1DMe (a neuropeptide FF analog) increased spontaneous and EFS (10 Hz)-evoked ACh release in a concentrationdependent manner at concentrations higher than 1 mM (Fig. 1) . A significant effect of 1DMe on EFS-evoked ACh release was seen at 10 m M (Fig. 1) . On the other hand, when muscarinic autoreceptors were activated by released ACh in the absence of atropine, 1DMe at 10 m M did not have any significant effect on the ACh release (Fig. 2) . Since naloxone increased both spontaneous and EFSevoked ACh releases in the presence of atropine in our previous study (10) , we next examined the interaction between augmentation of ACh release by 1DMe and naloxone. In the present study, naloxone at 1 mM increased the spontaneous and EFS-evoked ACh releases to 154.9 ± 10.1% and 134.3 ± 10.4% of the corresponding control, respectively (data not shown). Increasing the concentration of naloxone to 10 m M did not induce further effects on both ACh releases (spontaneous, 131.0 ± 12.3%; EFS, 123.2 ± 5.8%) (Fig. 3) . A combination of 10 mM 1DMe and 10 m M naloxone did not further increase ACh release more than either drug alone (Fig. 3) , showing no additive effect.
Morphine at 10 mM, which showed the maximal inhibitory effect on the ACh release (10), significantly inhibited the spontaneous and EFS-evoked ACh release to about 30% and 70% of the control, respectively (Fig. 4) . 1DMe counteracted the inhibitory effect of morphine on the EFSevoked ACh release in a concentration-dependent manner and completely suppressed morphine-induced inhibition at 10 mM (Fig. 4) . However, 1DMe plus morphine inhibited the spontaneous ACh release to a larger extent than morphine alone (Fig. 4) . Naloxone completely counteracted the inhibitory effect of morphine on EFS-evoked ACh release, but not the spontaneous release at 1 m M, and reversed both ACh releases at 10 m M (Fig. 5) . A combination of 1DMe and naloxone counteracted the inhibitory effects of morphine on both the ACh releases to the same extent as naloxone alone (Fig. 5) .
To confirm the specificity of the counteractive effect of 1DMe on the morphine-induced inhibition, we examined the effect of 1DMe on norepinephrine-induced inhibition of ACh release, which was previously reported in LMMP preparations (16) . Norepinephrine at 10 mM inhibited markedly the spontaneous ACh release to about 25% of control and slightly the EFS-evoked ACh release. 1DMe at 10 mM did not affect the inhibition of both the ACh releases by norepinephrine (Fig. 6 ).
DISCUSSION
Atropine (1 m M) was added to the bathing solution throughout the experiment to block the muscarinic autoinhibition by ACh released from the LMMP preparation and accumulated in the solution, because the muscarinic autoinhibition masked the inhibitory effects of morphine and endogenous opioid peptide on the ACh release as reported previously (10) . Under these conditions, a NPFF analog, 1DMe increased the spontaneous and EFS-evoked ACh release. These effects of 1DMe seem to be specific for the opioid-mediated mechanism for the following reasons. In the presence of naloxone at a maximal effective concentration, the stimulatory effect of 1DMe on ACh release from the LMMP preparation of guinea pig ileum was masked (Fig. 3) . 1DMe, as well as naloxone, counteracted the inhibitory effect of morphine on EFS-evoked ACh release. In addition, the reversal effects of 1DMe and naloxone on morphine-induced inhibition of ACh release were not additive (Fig. 5) . These results suggest that 1DMe and naloxone mediate the effects on the ACh release through the same pathway. 1DMe is shown to reverse morphine-induced analgesia which was inhibited by naloxone in mouse (17) and rat (3). It is well known that norepinephrine inhibits the ACh release from the LMMP preparation of guinea pig ileum by activation of a2-receptors located on the presynaptic plasma membrane of cholinergic neurons (18) . 1DMe did not affect the inhibitory effect of norepinephrine. Furthermore, 1DMe was ineffective in the absence of atropine, suggesting that it was unable to counteract the activation of muscarinic autoreceptors on ACh release. Thus, these results indicate that 1DMe has stimulatory effects on the ACh release by anti-opioid action. 1DMe does not possess a significant affinity towards opioid receptors (1) . Although an identification and characterization of two G protein-coupled receptors for NPFF were reported (19) , some effects of NPFF appeared to be mediated through opioid receptors and these effects were blocked by naloxone (1, 20) . Furthermore, chronic administration of NPFF induced downregulation of mu-opioid binding sites in the rat brain (21) . Further experiments are needed to clarify whether the stimulatory effect of 1DMe on the ACh release from LMMP preparation of guinea pig ileum is a direct or indirect action on opioid receptors.
It is also interesting that NPFF possesses potent antiand pro-opioid activity (22) . NPFF reversed the mu-receptor-mediated inhibitory effect on the Ca 2+ channel in rat spinal ganglion and dorsal raphe neurons (4, 5) . On the other hand, NPFF enhanced the antinociceptive effects by activation of delta-receptors in the rat brain slice (6) . These results suggest that NPFF might exhibit different effects via different types of opioid receptors. In the LMMP preparation of guinea pig ileum, morphine and endogenous opioid peptides were shown to inhibit the ACh release by activation of mu-receptors (11) . In mice, 1DMe was shown to preferentially reverse mu-receptor-mediated analgesia but increased delta-receptor-mediated one (17) . Therefore, the present study suggests that 1DMe increases ACh release by counteracting the activation of mu-receptors.
When muscarinic autoinhibition mechanism does not fully work, naloxone and opioid antagonists were shown to increase ACh release from the LMMP preparation of guinea pig ileum (10, 11) . In the present study, 1DMe increased spontaneous and EFS-evoked ACh release when the autoinhibition was weakened in the presence of atropine. These results suggest that 1DMe, as well as naloxone, increases the ACh release by counteracting endogenous opioid peptide(s) which tonically inhibits ACh release to a certain extent.
Although it was suggested that endogenous NPFF may play a role in the diarrhea observed in the morphine withdrawal syndrome in guinea pig ileum (12) , there is no direct evidence that NPFF is present in the guinea pig ileum. In the rat intestine, no NPFF immunoreactivity was seen in the autonomic nervous system or endocrine cells (23) . Interestingly, recent investigations have indicated that NPFF can function as an endogenous anti-opioid agent or a pro-opioid agent depending on the animal species (24) . There are also species differences in the distribution of NPFF receptors between the human and rat (19) . Therefore, further studies are needed to clarify the physiological role of NPFF in the gastrointestinal tract.
1DMe increased the spontaneous ACh release in the absence of morphine, but it further inhibited the spontaneous ACh release induced by morphine (Fig. 4) . This discrepancy can not be explained at present. Interestingly, the spontaneous ACh release from the LMMP preparation of guinea pig ileum is inhibited not only by mu-agonist (11) , but also by delta-agonist (data not shown). Since 1DMe increases delta-receptor-mediated analgesia as described above (17) , there may be a possibility that the effect of 1DMe on delta-receptors was manifested in the presence of morphine. Alternatively, two G protein-coupled receptors for NPFF were recently identified in the human and rat central nervous system, and mRNAs of these receptors were also detected in the gastrointestinal tract (19) . Although the physiological roles of these receptors are not clarified, there may be a possibility that the receptors are associated with the ACh release from LMMP preparation with different effects on the spontaneous and EFS-evoked ACh releases.
In conclusion, this study first demonstrated the effects of NPFF on neurotransmitter release. 1DMe, a NPFF analog, has a stimulatory effect on the spontaneous and EFSevoked release of ACh from the LMMP preparations of guinea pig ileum, probably by counteracting the inhibitory effect of endogenous opioid(s).
